Sentences with phrase «therapeutic cell transplantations»
However, the long - term genetic stability of this cell type remains to be determined, so as to avoid tumor formation following therapeutic cell transplantations.
https://discovery.lifemapsc.com/ Not exact matches
Scientists have suggested that such embryonic stem cells could be used for learning about genetic diseases, testing new drugs on cells grown in the lab, or growing healthy cells for therapeutic transplantation.
Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many patients with bone marrow failure.
Although many immunosuppressive strategies have failed, the recent use of autologous hematopoietic stem and progenitor cell (HSPC) transplantation has shown therapeutic promise.
However, coreceptor - specific ZFNs represent a novel therapeutic approach to recapitulate this success via autologous transplantation of gene - modified hematopoietic stem cells and mature CD4 + T cells.
Once this work is completed, a second stage is committed, in which researchers of I - Stem, in collaboration with specialists in animal models of diseases targeted by the therapeutic explore the effects of experimental transplantation of cells obtained laboratory.
As a result, they are currently being investigated as a cellular therapeutic for the treatment of autoimmune diseases and long - term patient and graft survival following solid organ transplantation, and allogeneic hematopoietic stem cell transplantation.
This new knowledge has paved the way for the therapeutic transfer of stem cells not only for the treatment of hematopoietic diseases by bone marrow transplantation â $» first attempted by E. Donnall Thomas, one of this bookâ $ ™ s editors, in 1957 â $» but also for the treatment of many other disorders.
Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of novel therapeutic options in the field of beta cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:
Executive Director — Stem Cells and Cellular Therapeutics Operations, Stanford University School of Medicine, USADr David DiGiusto is the Executive Director of Stem Cell and Cellular Therapeutic Operations for Stanford Hospital and Clinics and a Senior Academic Researcher in the Division of Stem Cell Transplantation and Regenerative Medicine at Stanford University.
A major impetus to the field was the report of a successful cure strategy through the transplantation of naturally HIV - resistant HSPCs - the so called «Berlin Patient» [3, 4]- highlighting the therapeutic potential of stem cell treatments.
Such performance - enhancing alterations will include reprogramming using non-integrating vectors or small molecules, the identification of the specific cell within the CS populations which provides therapeutic benefit, and the long - term consequences of CS cell transplantation.
Made major contributions to the field of immunology through his studies on immune tolerance in animal models, with particular focus on transplantation tolerance and autoimmunity, in addition to pioneering the use of therapeutic monoclonal antibodies against T cells, resulting in the development of Campath - 1H, the first humanised monoclonal antibody to be used therapeutically.
«Given the importance of stem cell - based transplantation therapies as well as the clinical significance of tumor metastastis to the bone marrow, there is great therapeutic potential in understanding these cellular interactions,» Sipkins said.
Currently available treatments including hydroxyurea, which is the only FDA approved drug for SCA, and hemopoietic stem cell transplantation all have significant limitations, so the search for new therapeutic options continues.
Additionally, for many blood cell malignancies such as certain types of leukaemia and multiple myeloma, HSC transplantation is an important therapeutic option.